ADC Therapeutics to Participate in March Investor Conferences

Rhea-AI Summary

ADC Therapeutics (NYSE: ADCT) will participate in investor conferences in March 2026, including TD Cowen 46th Annual Health Care Conference and Jefferies Biotech on the Beach Summit. Presentations include a corporate presentation by CEO Ameet Mallik on March 3, 2026 in Boston and one-on-one meetings on March 11, 2026 in Miami.

A webcast of the March 3 presentation will be available on the company’s Investors Events & Presentations page with a replay accessible for about 30 days.

News Market Reaction – ADCT

-0.45%

5 alerts

-0.45% News Effect

-$3M Valuation Impact

$580M Market Cap

0.1x Rel. Volume

On the day this news was published, ADCT declined 0.45%, reflecting a mild negative market reaction. Our momentum scanner triggered 5 alerts that day, indicating moderate trading interest and price volatility. This price movement removed approximately $3M from the company's valuation, bringing the market cap to $580M at that time.

Data tracked by StockTitan Argus on the day of publication.

Key Figures

TD Cowen conference date: March 3, 2026 TD Cowen time: 11:50 a.m. EST Jefferies summit date: March 11, 2026 +1 more

4 metrics

TD Cowen conference date March 3, 2026 TD Cowen 46th Annual Health Care Conference presentation date

TD Cowen time 11:50 a.m. EST Scheduled time for corporate presentation

Jefferies summit date March 11, 2026 Jefferies Biotech on the Beach Summit one-on-one meetings

Webcast replay period 30 days Replay of conference webcast accessible via investor website

Market Reality Check

Price: $4.39 Vol: Volume 1,129,891 is 1.39x...

normal vol

$4.39 Last Close

Volume Volume 1,129,891 is 1.39x the 20-day average of 815,227 shares, indicating elevated activity ahead of this conference notice. normal

Technical Trading above the 200-day MA at $3.47 and within 8.12% of its 52-week high, up from a low that was 320% below current levels.

Peers on Argus

ADCT was up 7.56% while key biotech peers like AUTL, YMAB, AURA, and BNTC showed...

1 Up

ADCT was up 7.56% while key biotech peers like AUTL, YMAB, AURA, and BNTC showed smaller gains (up between 0.23% and 2.37%) and LXRX declined 0.66%, suggesting a stock-specific move rather than a broad sector rotation.

Common Catalyst One peer, AUTL, also issued an investor conference participation notice, indicating a shared conference calendar but not a broad price move across the group.

Historical Context

5 past events · Latest: Feb 23 (Neutral)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Feb 23	Royalty amendment	Neutral	+7.6%	Amended HealthCare Royalty agreement and issued equity-linked warrants.
Feb 02	Equity grants	Neutral	+0.0%	Inducement plan option grants to new employees under NYSE exemption.
Jan 08	Prelim results, updates	Positive	-2.2%	Preliminary 2025 revenue, cash runway to 2028, and LOTIS trial updates.
Jan 08	Prelim results, updates	Positive	-2.2%	Repeat of preliminary 2025 revenue and clinical catalyst disclosure.
Jan 08	Conference notice	Neutral	-2.2%	J.P. Morgan Healthcare Conference presentation and webcast availability.

Pattern Detected

Recent history shows mixed reactions: financing and capital-structure news aligned with positive price moves, while preliminary financial/clinical updates and some conference notices coincided with price declines, indicating inconsistent trading responses to news.

Recent Company History

Over the last few months, ADC Therapeutics announced an amended royalty financing with HealthCare Royalty, multiple equity grants to employees and executives, preliminary unaudited 2025 revenue and cash figures with clinical program updates, and participation in the 44th Annual J.P. Morgan Healthcare Conference on January 15, 2026. The royalty amendment on Feb 23, 2026 saw a 7.56% gain, while the preliminary 2025 update on Jan 8, 2026 and the J.P. Morgan conference notice each coincided with a -2.19% move, highlighting variable reactions to both fundamental and investor-relations events.

Regulatory & Risk Context

Active S-3 Shelf · $71,341.46

Shelf Active

Active S-3 Shelf Registration 2025-12-09

$71,341.46 registered capacity

An effective S-3/A shelf amendment dated 2025-12-09 updated auditor consent and estimated offering-related registration expenses of $71,341.46, including a SEC fee of $8,341.46, without changing the underlying prospectus terms.

Market Pulse Summary

This announcement outlines ADC Therapeutics’ participation in March investor events, including a TD ...

Analysis

This announcement outlines ADC Therapeutics’ participation in March investor events, including a TD Cowen presentation on March 3, 2026 at 11:50 a.m. EST and Jefferies one-on-one meetings on March 11, 2026. Webcasts and 30-day replays increase management’s visibility to investors. In context of recent royalty financing changes and preliminary 2025 updates, these conferences offer a platform to reinforce the company’s commercial and clinical narrative without introducing new fundamentals in this release.

Key Terms

antibody drug conjugates

1 terms

antibody drug conjugates medical

"a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs)"

Antibody drug conjugates are targeted medicines that combine an antibody, which seeks out specific markers on diseased cells, with a powerful drug that is released only when the antibody binds its target. Think of it as a guided missile that delivers a toxic payload directly to its target, reducing damage to healthy cells; investors watch them because successful ADCs can offer high-value, niche treatments and drive strong revenue and patent-based protection for developers.

AI-generated analysis. Not financial advice.

LAUSANNE, Switzerland, Feb. 24, 2026 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced participation in upcoming investor conferences in March:

TD Cowen 46th Annual Health Care Conference
Date: Tuesday, March 3, 2026
Presentation Time: 11:50 a.m. EST
Format: Corporate presentation
Speaker: Ameet Mallik, Chief Executive Officer
Location: Boston, MA
To register for the webcast, click here.

Jefferies Biotech on the Beach Summit
Date: March 11, 2026
Format: One-on-one meetings
Location: Miami, FL

A live webcast of the presentation will be available via the Events & Presentations page in the Investors section of ADC Therapeutics' website, ir.adctherapeutics.com with a replay available for approximately 30 days following.

About ADC Therapeutics
ADC Therapeutics (NYSE: ADCT) is a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), transforming treatment for patients through our focused portfolio with ZYNLONTA (loncastuximab tesirine-lpyl).

ADC Therapeutics' CD19-directed ADC ZYNLONTA received accelerated approval by the FDA and conditional approval from the European Commission for the treatment of relapsed or refractory diffuse large B-cell lymphoma after two or more lines of systemic therapy. ZYNLONTA is also in development in combination with other agents and in earlier lines of therapy.

Headquartered in Lausanne (Biopôle), Switzerland, with operations in New Jersey, ADC Therapeutics is focused on driving innovation in ADC development with specialized capabilities from clinical to manufacturing and commercialization. Learn more at adctherapeutics.com and follow us on LinkedIn.

Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. In some cases you can identify forward-looking statements by terminology such as "may", "will", "should", "would", "expect", "intend", "plan", "anticipate", "believe", "estimate", "predict", "potential", "seem", "seek", "future", "continue", or "appear" or the negative of these terms or similar expressions, although not all forward-looking statements contain these identifying words. Forward-looking statements are subject to certain risks and uncertainties that can cause actual results to differ materially from those described. Factors that may cause such differences include, but are not limited to: changes to the preliminary unaudited Q4 and full year 2025 net product revenue and cash and cash equivalents as of December 31, 2025; expected cash runway at least to 2028 which assumes use of minimum liquidity amount required to be maintained under its loan agreement covenants; whether future LOTIS-7 clinical trial results will be consistent with or different from the LOTIS-7 data presented by the Company on December 3, 2025, the timing, publication and outcome of the full LOTIS-7 trial, compendia inclusion and regulatory strategy and the commercial opportunity; the timing of the PFS events and topline data release for LOTIS-5 and the results of the trial, the timing for the sBLA submission and full FDA approval; the Company's ability to grow ZYNLONTA® revenue in the United States and potential peak revenue; the ability of our partners to commercialize ZYNLONTA® in foreign markets, the timing and amount of future revenue and payments to us from such partnerships and their ability to obtain regulatory approval for ZYNLONTA® in foreign jurisdictions; the timing and results of the Company's clinical trials; the timing, publication and results of investigator-initiated trials including those studying FL and MZL and the potential regulatory and/or compendia strategy and the future opportunity; the timing and outcome of regulatory submissions for the Company's products or product candidates; actions by the FDA or foreign regulatory authorities; projected revenue and expenses; the Company's indebtedness, including HealthCare Royalty Management and Blue Owl and Oaktree facilities, and the restrictions imposed on the Company's activities by such indebtedness, the ability to comply with the terms of the various agreements and repay such indebtedness and the significant cash required to service such indebtedness; and the Company's ability to obtain financial and other resources for its research, development, clinical, and commercial activities; and the uncertainties of international trade policies, including tariffs, sanctions, trade barriers and most favored nation drug pricing and the potential impact they may have on our business, financial condition, and results of operations. Additional information concerning these and other factors that may cause actual results to differ materially from those anticipated in the forward-looking statements is contained in the "Risk Factors" section of the Company's Annual Report on Form 10-K and in the Company's other periodic and current reports and filings with the U.S. Securities and Exchange Commission. These statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance, achievements or prospects to be materially different from any future results, performance, achievements or prospects expressed in or implied by such forward-looking statements. The Company cautions investors not to place undue reliance on the forward-looking statements contained in this document.

CONTACTS:
Investors and Media
Nicole Riley
ADC Therapeutics
Nicole.Riley@adctherapeutics.com
+1 862-926-9040

View original content to download multimedia:https://www.prnewswire.com/news-releases/adc-therapeutics-to-participate-in-march-investor-conferences-302694727.html

SOURCE ADC Therapeutics SA

FAQ

When will ADC Therapeutics (ADCT) present at TD Cowen 2026 and who is speaking?

ADC Therapeutics will present on March 3, 2026 and the speaker is CEO Ameet Mallik. According to the company, the format is a corporate presentation at 11:50 a.m. EST in Boston and a live webcast will be provided on the investor site.

How can investors access the ADC Therapeutics (ADCT) March 3, 2026 webcast?

Investors can access the webcast via the company’s Events & Presentations investor page. According to the company, the live webcast will appear on the Investors page and a replay will be available for approximately 30 days after the presentation.

What is ADC Therapeutics (ADCT) schedule at Jefferies Biotech on the Beach Summit in March 2026?

ADC Therapeutics is scheduled for one-on-one meetings on March 11, 2026 in Miami. According to the company, the format is individual meetings rather than a public corporate presentation at that event.

Will ADC Therapeutics (ADCT) provide a replay of its March 3, 2026 presentation and for how long?

Yes, a replay will be available for about 30 days following the March 3 presentation. According to the company, the replay will be posted on the Events & Presentations page in the Investors section of its website.

Where will ADC Therapeutics (ADCT) presentations take place and are they open to registrants?

The TD Cowen presentation is in Boston and Jefferies meetings are in Miami; registration is required for the webcast. According to the company, registrants can access the live webcast via the investor site and must register where indicated.